B

Bioverge

9 employees

Bioverge is a venture capital firm specializing in emerging healthcare startups.

Investor insights

Sectors invested in

Biotechnology31
Health Care21
Therapeutics12
Medical11
Life Science9
Medical Device7
Biopharma6
Wellness4
Artificial Intelligence3
Neuroscience3
Drug Discovery3
ALS2
Neurodegenerative Disease2
Alzheimer2
PSP2
Therapies2
Biotech2
Psychiatry2
Depression Treatment2
Anxiety Treatment2

Funding rounds participated in

$1.5M sweet spot round size

Most of their 43 investments are in rounds between $4.5M and $10M

Investor type

Venture Capital

Basic info

Industry

venture capital and private equity principals

Sectors

Biotechnology
Crowdfunding
Gene Therapy
Investing
Digital Health
AI
Healthcare Technology
Medical Devices
3D Printing
angel investing
Health Care
Impact investing
Healthcare
TechBio
Microbiome
Venture Capital

Date founded

2016

Investments made

M

My Diabetes Tutor Inc. - Diabetes Education Telehealth raised undisclosed on July 27, 2023

Investors: ChARM Health and Bioverge

M

Modulo Bio raised $8M on June 1, 2023

Investors: Hawktail, Refactor Capital, Initialized Capital, Spacecadet, Cantos Ventures and Bioverge

M

Modulo Bio raised $8M on June 1, 2023

Investors: Spacecadet, Initialized Capital, Cantos Ventures, Refactor Capital, Hawktail and Bioverge

E

Eigen Therapeutics raised $7M on December 8, 2022

Investors: Mount Pleasant Ventures, Hawktail and Bioverge

G

GigaMune raised undisclosed on November 1, 2022

Investors: Boost VC and Bioverge

N

Notable raised undisclosed on July 1, 2022

Investors: Bioverge

F

Foresight Mental Health raised undisclosed on June 23, 2022

Investors: Polaris Partners, Sequoia Heritage, JAZZ Venture Partners and Bioverge

O

Octant raised $80M on April 28, 2022

Investors: Andreessen Horowitz, Catalio Capital Management, Flucas Ventures, Bristol-Myers Squibb, UK, Allen & Company LLC. and Bioverge

A

Alto Neuroscience raised undisclosed on March 18, 2022

Investors: Bioverge

B

Bionaut Labs raised undisclosed on March 16, 2022

Investors: Bioverge

FAQ